Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients

被引:19
作者
Ben Gacem, R. [1 ]
Hachana, M. [1 ]
Ziadi, S. [1 ]
Amara, K. [1 ]
Ksia, F. [1 ]
Mokni, M. [1 ]
Trimeche, M. [1 ]
机构
[1] Farhat Hached Hosp, Dept Pathol, Sousse 4000, Tunisia
关键词
Breast cancer; BRCA1; BRCA2; Methylation; Tunisia; MAMMARY EPITHELIAL-CELLS; DNA-REPAIR DEFECT; SPORADIC BREAST; PROMOTER METHYLATION; OVARIAN-CANCER; CHROMOSOME; 13Q12-Q13; HEREDITARY BREAST; ESTROGEN-RECEPTOR; TUMORS; HYPERMETHYLATION;
D O I
10.1016/j.canep.2011.09.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to evaluate the contribution of the BRCA1 and BRCA2 promoter methylation in the pathogenesis of sporadic breast cancer in Tunisian patients. Methods: Breast carcinoma tissues (n = 117) and available paired normal breast tissues (n = 65) from Tunisian women who had no family history were investigated for the methylation status of BRCA1 and BRCA2 promoters using methylation-specific PCR. Breast specimens from women without carcinoma (16 fibroadenomas and 5 mastopathies) were used as control. Results: Hypermethylation of BRCA1 and BRCA2 promoters was detected respectively in 60.7% and 69.2% of the carcinoma tissues, and in only 7.7% and 4.6% of the paired normal breast tissues. None of the fibroadenomas and mastopathies showed hypermethylation. Correlations were found between BRCA1 and BRCA2 hypermethylation and decrease in their mRNA expression (p = 0.02 and p = 0.009, respectively). Moreover, BRCA1 methylation correlates with patients age (p = 0.01) and triple negative (ER-, PR-, HER2-) tumors (p = 0.01). Patients with methylated BRCA1 and/or BRCA2 had a significant prolonged survivals compared to those with unmethylated tumors (p = 0.002). Conclusion: Our results suggest an important role of BRCA1 and BRCA2 promoter methylation in breast cancer development in the Tunisian population. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:190 / 197
页数:8
相关论文
共 63 条
[11]   BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer [J].
Chen, Yanglin ;
Zhou, Jing ;
Xu, Ye ;
Li, Zhaosheng ;
Wen, Xianzi ;
Yao, Lihua ;
Xie, Yuntao ;
Deng, Dajun .
CANCER SCIENCE, 2009, 100 (09) :1663-1667
[12]   LOSS OF HETEROZYGOSITY IN SPORADIC BREAST-TUMORS AT THE BRCA2 LOCUS ON CHROMOSOME 13Q12-Q13 [J].
CLETONJANSEN, AM ;
COLLINS, N ;
LAKHANI, SR ;
WEISSENBACH, J ;
DEVILEE, P ;
CORNELISSE, CJ ;
STRATTON, MR .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1241-1244
[13]   Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers [J].
Collins, N ;
Wooster, R ;
Stratton, MR .
BRITISH JOURNAL OF CANCER, 1997, 76 (09) :1150-1156
[14]  
Dobrovic A, 1997, CANCER RES, V57, P3347
[15]   Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors [J].
Esteller, M ;
Silva, JM ;
Dominguez, G ;
Bonilla, F ;
Matias-Guiu, X ;
Lerma, E ;
Bussaglia, E ;
Prat, J ;
Harkes, IC ;
Repasky, EA ;
Gabrielson, E ;
Schutte, M ;
Baylin, SB ;
Herman, JG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (07) :564-569
[16]   CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future [J].
Esteller, M .
ONCOGENE, 2002, 21 (35) :5427-5440
[17]   Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].
Farmer, H ;
McCabe, N ;
Lord, CJ ;
Tutt, ANJ ;
Johnson, DA ;
Richardson, TB ;
Santarosa, M ;
Dillon, KJ ;
Hickson, I ;
Knights, C ;
Martin, NMB ;
Jackson, SP ;
Smith, GCM ;
Ashworth, A .
NATURE, 2005, 434 (7035) :917-921
[18]  
Feng Jing, 2009, Ai Zheng, V28, P436
[19]  
FERLAY J, 2000, IARC CANCERBASE, V5
[20]   BRCA1 and BRCA2:: chemosensitivity, treatment outcomes and prognosis [J].
Foulkes, William D. .
FAMILIAL CANCER, 2006, 5 (02) :135-142